Free Papers

Three year results from the SPECTRUM registry: 702 eyes treated with a Schlemm’s Canal Microstent as a standalone procedure for glaucoma

Free Paper Details

First Author: L.Au UK

Co Author(s):                        

Abstract Details

Purpose:

The purpose of this evaluation is to present outcomes in the 702 eyes (from 575 patients) who underwent Hydrus implantation as a standalone treatment for glaucoma.

Setting:

The study population consisted of pateints with a glaucoma diagnosis drawn from 50 clinical sites located in 17 countires in Europe, Asia, Australia, South and Central America, and Canada.

Methods:

Patients were treated according to the surgeon’s standard of care and results were entered into an online database. Mean age was 70 years old and 50% of subjects were female. Subjects were 75% Caucasian, 12% Hispanic, 5% Black and 5% Asian. Prior ocular history included 36% with prior laser trabeculoplasty and 16% with prior incisional glaucoma surgery. POAG was the most common form of glaucoma (76%) but other types of glaucoma were represented, including pseudoexfoliation (7%), pigmentary (3%) and angle closure (4%). In terms of lens status, 34% were phakic and 65% pseudophakic.

Results:

Results demonstrate significant reduction in IOP and medications for at least 3 years postoperative. Baseline mean IOP was 21.1 mmHg on 2.6 categories of glaucoma medications. Mean IOP reduction was 4.9 mmHg at 1 year, 5.7 mmHg at 2 years and 6.1 mmHg at 3 years (p < 0.05 for all time points). Mean reduction in glaucoma medications was 1.1 meds at 1 year, 1.0 meds at 2 years and 0.9 meds at 3 years (p < 0.05 for all time points). The rate of adverse events was approximately 1% intraoperative and 7% cumulative through 3 years postoperative.

Conclusions:

The Hydrus® Microstent significantly reduced both IOP and glaucoma medications as a standalone treatment. The results were maintained for at least three years in a large and diverse population. There were no significant safety concerns.

Financial Disclosure:

... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... research is funded, fully or partially, by a competing company, ... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... receives consulting fees, retainer, or contract payments from a competing company